Clene (CLNN) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free CLNN Stock Alerts $0.34 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBullish Clene Insiders Loaded Up On US$9.58m Of Stockfinance.yahoo.com - April 23 at 6:39 PMClene's (CLNN) Buy Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - April 18 at 5:42 AMThe Analyst Verdict: Clene In The Eyes Of 5 Expertsbenzinga.com - April 17 at 6:20 PMClene stock rallies 52% post-market on MS drug datamsn.com - April 16 at 8:44 PMEvidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meetingglobenewswire.com - April 16 at 4:01 PMClene Inc. (NASDAQ:CLNN) Short Interest Down 38.5% in Marchmarketbeat.com - March 28 at 6:01 PMClene (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MStheglobeandmail.com - March 27 at 12:08 PM3 Penny Stocks That Could Be Multibaggers in the Making: March Editioninvestorplace.com - March 26 at 2:19 PMClene's (CLNN) "Buy" Rating Reaffirmed at Benchmarkmarketbeat.com - March 20 at 8:37 AMIBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etheringtonfinance.yahoo.com - March 19 at 9:29 AMClene Inc Ordinary Sharesmorningstar.com - March 17 at 2:20 AMBuy Rating Affirmed for Clene Amid Positive ALS Drug Data and Market Dynamicsmarkets.businessinsider.com - March 16 at 1:32 AMHC Wainwright Weighs in on Clene Inc.'s FY2028 Earnings (NASDAQ:CLNN)marketbeat.com - March 15 at 8:15 AMClene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®globenewswire.com - March 15 at 8:00 AMClene Inc. (NASDAQ:CLNN) Short Interest Updatemarketbeat.com - March 14 at 10:30 PMClene Inc.: Clene Reports Full Year 2023 Financial Results and Recent Operating Highlightsfinanznachrichten.de - March 13 at 6:21 PMBreaking Down Clene: 4 Analysts Share Their Viewsmarkets.businessinsider.com - March 13 at 6:21 PMClene: Q4 Earnings Insightsbenzinga.com - March 13 at 1:21 PMClene Reports Full Year 2023 Financial Results and Recent Operating Highlightsglobenewswire.com - March 13 at 8:00 AMClene to Present at the 36th Annual ROTH Conferencefinance.yahoo.com - March 7 at 12:31 PMBuy Rating Affirmed for Clene’s CNM-Au8 on Promising Long-Term Clinical Outcomesmarkets.businessinsider.com - February 29 at 8:44 PMClene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024globenewswire.com - February 29 at 8:00 AMBuy Rating Affirmed for Clene Amidst Strong Clinical Data and Financial Stabilitymarkets.businessinsider.com - February 22 at 9:10 PMClene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programsmarkets.businessinsider.com - February 22 at 9:48 AMCLNN Mar 2024 1.000 putfinance.yahoo.com - February 17 at 3:54 PMCLNN Mar 2024 3.000 callfinance.yahoo.com - February 17 at 9:56 AMClene (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interviewtheglobeandmail.com - February 8 at 10:51 AMIbogaine By David Dardashti Offers Free Online Support for Post-Treatment Carefinance.yahoo.com - February 6 at 3:16 PMClene (NASDAQ: CLNN) Reports Statistically Significant Long-Term Improvements for VISIONARY-MS Participantstheglobeandmail.com - February 6 at 3:16 PMClene Inc. (NASDAQ:CLNN) Shares Sold by Vivo Capital LLCmarketbeat.com - February 6 at 1:40 PMClene VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatmentfinance.yahoo.com - January 24 at 10:48 AMClene (NASDAQ: CLNN) VISIONARY-MS Trial Data May Support CNM-Au8(R) as MS Treatmenttheglobeandmail.com - January 23 at 2:46 PMClene Inc. announces positive results from CNM-Au8 results from MS trialproactiveinvestors.com - January 11 at 2:33 PMClene Announces Significant Positive Results from LTE VISIONARY-MS Trialfinance.yahoo.com - January 10 at 1:53 PMBuy Rating Affirmed: Clene’s CNM-Au8 Shows Promising Efficacy in MS Treatment Studymarkets.businessinsider.com - January 9 at 7:38 PMClene Announces Improvement In Vision, Cognition With CNM-Au8 Treatmentmarkets.businessinsider.com - January 8 at 2:41 PMOptimistic Buy Rating for Clene’s Stock Backed by Promising ALS Survival and Biomarker Datamarkets.businessinsider.com - December 22 at 1:06 AMNasdaq Gains 100 Points; CarMax Earnings Top Viewsmsn.com - December 21 at 8:06 PMClene down 33% as FDA denies accelerated approval for ALS therapymsn.com - December 21 at 10:05 AMUS FDA finds Clene's trial data for ALS drug to be insufficientreuters.com - December 21 at 10:05 AMClene Provides Update on ALS Clinical Development Meeting With FDAfinance.yahoo.com - December 21 at 10:05 AMClene Lead Drug Candidate Featured in Peer-Reviewed Publicationfinance.yahoo.com - December 15 at 6:38 PMClene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseasesmarkets.businessinsider.com - December 15 at 8:37 AMClene Inc Ordinary Shares CLNNmorningstar.com - December 13 at 3:27 PMClene's Long-Term Follow-Up Data Shows Significantly Improved Survival in ALS Patientsfinance.yahoo.com - December 12 at 12:26 PMClene Capitalizing on Promising Chemical and Therapeutic Properties of Nanocrystalsfinance.yahoo.com - November 23 at 12:01 PMInsider Spends US$103k Buying More Shares In Clenefinance.yahoo.com - November 15 at 8:46 AMClene Announces Q3 2023 Financial Results, Operating Highlightsfinance.yahoo.com - November 9 at 1:38 PMBenchmark Co. Keeps Their Buy Rating on Clene (CLNN)markets.businessinsider.com - November 9 at 8:37 AMClene GAAP EPS of -$0.02, revenue of $0.11Mmsn.com - November 7 at 1:16 PM Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. CLNN Media Mentions By Week CLNN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.080.44▲Average Medical News Sentiment CLNN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼42▲CLNN Articles Average Week Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ELDN News Today MRKR News Today UNCY News Today CARA News Today NRXP News Today PMN News Today OCUP News Today BCTX News Today RMTI News Today BOLT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
